Stem Cell Therapy in Autism Spectrum Disorders

Open Label Study of Autologous Bone Marrow Mononuclear Cells in Autism Spectrum Disorders

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01974973

Enrollment

Registered

2013-11-04

Start date

2009-08-31

Completion date

2016-05-31

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorders

Keywords

autism spectrum disorders, stem cells

Brief summary

The purpose of this study was to study the effect of stem cell therapy on common symptoms in patients with autism spectrum disorders

Interventions

PROCEDUREAutologous bone marrow mononuclear cell transplantation

Intrathecal autologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

6 Months to 40 Years

Healthy volunteers

Inclusion criteria

* Diagnosed cases of any type of autism spectrum disorders * age above 6 months

Exclusion criteria

* presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[Hemoglobin \< 8\] * any bone marrow disorder * space occupying lesion in brain * other acute medical conditions such as respiratory infection and pyrexia

Design outcomes

Primary

Measure	Time frame
Improvement in the scales for Autism spectrum disorders	Six months

Secondary

Measure	Time frame
Positron Emission Tomography- computed tomography to study change in brain metabolism	six months

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026